SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (445)9/1/2003 5:13:21 PM
From: Icebrg  Read Replies (1) of 631
 
Fresh from the pipeline
Adalimumab

Bornadata Bain1 & Melanie Brazil2
1 Bornadata Bain is at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA.
2 Melanie Brazil is at Nature Reviews Drug Discovery.

Adalimumab (Humira; Abbott), an antibody that binds specifically to the inflammatory cytokine TNF-, was approved by the US FDA for the treatment of moderate to severe rheumatoid arthritis in December 2002. Does the launch of adalimumab, which is the first fully human antibody to be approved as a therapeutic, sound the death knoll for chimeric and humanized antibodies?

nature.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News